

Research Paper

Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer

Jennifer Podolak¹, Kristi Eilers¹, Timothy Newby¹, Rachel Slotke¹, Erin Tucker¹, Susan B. Olson², Hui-Wen Lue¹, Jack Youngren³, Rahul Aggarwal³, Eric J. Small³, Julie N. Graff¹, Joshi J. Alumkal¹, Tomasz M. Beer¹ and George V. Thomas^{1,2}

¹Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA

²Department of Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, OR, USA

³School of Medicine, University of California, San Francisco, CA, USA

Correspondence to: George V. Thomas, **email:** thomasge@ohsu.edu

Keywords: prostate cancer, circulating tumor cells, androgen receptor, metastases, metastatic castration resistant prostate cancer

Received: September 30, 2016

Accepted: February 27, 2017

Published: March 13, 2017

Copyright: Podolak et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Increased *AR* activity has been shown to be preserved in spatially distinct metastatic tumors from the same patient suggesting the requirement for lineage-specific dependencies for metastatic castration resistant prostate cancer (mCRPC). Amplification of the *AR* gene is a common mechanism by which mCRPC increase *AR* activity. To determine whether *AR* amplification in circulating tumor cells (CTC) could complement metastatic tissue biopsies in men undergoing treatment for mCRPC, we developed a novel two-step assay to isolate CTCs and subsequently analyzed *AR* amplification status in CTCs and matched biopsy tissue from the same patient by fluorescence *in situ* hybridization (FISH). *AR* gene status in CTCs showed strong concordance with *AR* gene status in matched tissue samples in 24 of 25 patients (Correlation: 96%; Kappa: 0.83; Sensitivity: 100%, Specificity: 83%). Our work demonstrates that *AR* amplification is conserved between CTCs and biopsies and that CTCs can serve as non-invasive surrogate to document *AR* amplification in mCRPC.

INTRODUCTION

AR signaling is the primary driver of prostate cancer, and subsequently, medical castration with androgen deprivation therapy (ADT) is the backbone of all treatments in men with metastatic prostate cancer [1–4]. However, these tumors invariably become resistant to ADT, with the emergence of CRPC, which is ultimately fatal. Increased *AR* signaling despite castrate levels of testosterone is responsible for CRPC in the majority of men. Importantly, the majority of spatially distinct metastases within individual patients with mCRPC continue to exhibit increased *AR* signaling [5]. Hematogenous dissemination of cancer cells is a critical step in the development of metastases. Consequently, CTCs in the bloodstream potentially link the primary tumor with their anatomically and chronologically distinct metastatic progenies [6, 7]. Therefore, our objective was to determine whether CTCs

could serve as non-invasive surrogates for biopsies of metastatic tissues. Specifically, we determined whether men treated with more potent androgen signaling inhibitors (ASI) such as abiraterone and enzalutamide continue to exhibit higher androgen signaling activity [8–10]. One mechanism of increased *AR* signaling in CRPC is through amplification of the *AR* gene [5]. We developed a platform-agnostic protocol to capture CTCs and to measure *AR* amplification status in CTCs from men with mCRPC undergoing treatment, and we evaluated the concordance of *AR* amplification status with matched metastatic biopsies.

RESULTS

Validation of CTC capture protocol and *AR* FISH

To demonstrate the validity of our CTC isolation method, we first spiked 10, 250, 500 and 1000 LNCAP

cells into 15 mls of normal whole blood. The blood/cell mixture was diluted 1:1 with PBS. Fifteen mls of Ficoll Paque Plus (GE Healthcare #17-1440-02) was added to a 50 ml Leucosep filter tube (Greiner Bio-One #227290P) and the blood/cell mixture was added to Leucosep tube and spun at 1600 g for 20 min without brake. After centrifugation, the PBMC layer containing spiked LNCAP cells was removed using a transfer pipet and placed in a clean 15 ml conical and pelleted at 400 g for 4 min. Cell pellet was resuspended in 1 ml of donor blood set aside at the start of the assay. Fifty microliters of RosetteSep CTC enrichment cocktail (Stemcell # 15137C) was added to each sample and incubated at room temperature for 20 minutes. After incubation, 4 ml of Ficoll Paque Plus was added to a new 15 ml conical for each sample. Enriched blood samples were brought to a total volume of 6 ml with PBS and was gently layered onto the Ficoll layer. Samples were spun at 1200 rpm for 20 min without brake. Enriched cell layer was removed and placed in a new 15 ml conical. PBS was added to enriched cells to bring volume to 9 ml. One ml of red lysis buffer was added and conicals were incubated on a rocker for 15 min. Cell samples were pelleted at 400 g for 4 min and supernatant was decanted. Remaining cells were resuspended in 200 ul of 4% paraformaldehyde. The re-suspended cells were cytospun using a Thermo Scientific Cytospin 4 to create 2 slides per sample, 100 ul of suspension per slide. Funnel and slide assembly was constructed and 100 ul of cell suspension was added to each funnel. Slides were spun at 700 g for 3 min. Funnel and slide were disassembled; slides were allowed to air dry and then were stored at -80°C for up to six months. To quantify the capture rate of this method, slides were stained with CK18 (green) and CD45 (pink) markers to differentiate epithelial cells from WBCs. Slides were scanned using a Panoramic Midi slide scanner (Perkin Elmer) and quantified by visual inspection. Our recovery assays were performed by spiking between 10 and 1000 LNCAP cells into donor blood samples. Multiple recovery assays were performed with an average yield of 38%. Despite the low recovery rate, we were able to capture cells in our samples that contained only 10 spiked cells providing confidence that CTC capture would be attainable in patient samples. After capturing full slide images using Panoramic MIDI scanner, the slides were reprocessed for *AR* gene status using FISH. Slides were re-imaged. LNCAP cells possessed 2 copies of *AR* and 2 copies *X CEP* gene and were identified by relocating the CK18 positive cells. White blood cells contained zero or one copy of *AR* gene and had zero or one copy of *X CEP* control. No white blood cells expressed greater than 1 copy of *X CEP* control, consistent with prior reported results [11]. (Figure 1).

***AR* FISH status in CTCs revealed a strong concordance with *AR* status in matched tumor tissue**

We compared *AR* gene status in CTC samples of 25 patients with CRPC status with the *AR* gene status of

patient matched tumor tissue in a blinded approach (see Table 1 for clinical details). Our studies resulted in an observed kappa of 0.8837. The median interval between CTC samples and tissue sample was 3.72 days. The number of CTCs per patient sample ranged from 1–33. We were able to determine the *AR* gene status of all patient CTC samples and found that *AR* amplification occurred in 19 of 25 patients. Analysis of *AR* FISH status was performed and determined on all patient tissue samples. We were able to correlate all patient CTC samples with a matched tissue sample to determine *AR* gene amplification status. Nineteen patients had *AR* gene amplification status expressed in CTCs and tumor sample. Five patients had no *AR* gene amplification in CTC samples and tissue sample. One patient expressed *AR* gene amplification in CTCs, but not in the biopsy, perhaps representing heterogeneity among different metastatic sites on the same patient (Figure 2). Overall, CTC samples revealed the same *AR* gene status as the biopsy sample in 24 of 25 cases (Correlation:96%; Kappa: 0.83; Sensitivity: 100%, Specificity: 83%). Fifteen subjects had abiraterone or enzalutamide treatment prior to biopsy compared to ten subjects that did not receive these drugs. No statistical differences were observed between treatment and *AR* signaling activity. We also compared *AR* signaling to PSA, Gleason score and LDH and found no significant differences between treatment groups or those that responded to treatment and those that progressed.

CTCs reveal heterogeneous *AR* amplification in CRPC patients

We observed inter- and intra-patient heterogeneity for *AR* amplification (Figure 3, and Table 2). Thirteen of twenty-five patients (52%) exhibited a mixture of *AR* amplified positive and negative CTCs in the same sample. Using the FishQuant software, *AR* FISH scores were determined by the ratio of gene probe/control probe (G/C). For amplified, CTCs, we assigned G/C 2.5 as weak *AR* amplification, G/C > 2.5 and < 4 medium amplification and G/C > 4 defined strong *AR* amplification. Twelve of twenty patients (60%) exhibited different levels of *AR* amplification and points to multiple temporal and spatial tumor clones in CTCs from patients with CRPC, that may be the result of selective pressures from treatment or evolution of the cancer as it progresses from hormone sensitive to CRPC.

***AR* amplification in patients with sequential biopsies**

We also investigated *AR* amplification in three patients with sequential samples collected before starting treatment and at progression (Figure 4). The CTC *AR* status matched the biopsy *AR* status in all three patients. Importantly, one patient (ID# 58) developed *AR* amplification at progression and this was picked up both in his metastatic liver biopsy and CTCs drawn at the same time.

DISCUSSION

Hematogenous dissemination of cancer cells is a critical step in the development of metastases [12]. Consequently, CTCs in the bloodstream potentially link the primary tumor with their anatomically and chronologically distinct metastatic progenies. Patients with higher numbers of CTCs in their bloodstream do worse than those with none, and this is especially true for prostate cancer [13]. This then has been the basis of CTC capture devices, which were developed to enumerate the number of CTCs in drawn blood [14]. Our method, which can be performed in either research or clinical setting uses a combination of red cell lysis and WBC depletion to capture CTCs which can be then characterized by any surface marker and identified through an automated scanning imaging platform.

Circulating tumor cells offer a non-invasive method of determining the biological status of individual tumors, treatment evaluation and progression. The shedding of CTCs from the primary tumor is known to play a role in mCRPC. Studies have shown that the number of CTCs decreases with response to treatment and increases with disease progression. The study of genomic makeup of CTCs has been vastly increasing to include genomic and RNA profiling to identify of key drivers in CRPC. Recent studies have included *PTEN*, *ERG* and *AR* gene status

and mRNA profiling in single circulating tumor cells [11, 15]. Molecular profiling of CTCs proves difficult due to low cell number and the high cost of assay platforms and routine testing, however, the biological information that can be derived from an individual's CTC profile may lead to improved individualized treatment.

Since *AR* amplification is a major driver of CRPC and persists despite newer Androgen Signaling Inhibitors such as abiraterone and enzalutamide, we evaluated *AR* amplification status by FISH. Simultaneously, we collected metastatic CRPC biopsies and performed *AR* FISH on FFPE tissues. *AR* gene status detected in CTCs showed strong concordance with *AR* gene status in matched tissue samples in 24 of 25 patients (96%).

Intriguingly, this study through our ability to identify and quantify single CTCs revealed that there is striking intra-patient heterogeneity in *AR* amplification status, both binary (i.e. amplified and non-amplified CTCs in the same patient) and the degree of amplification (low to high number of *AR* gene copies). This may reflect selective pressures brought on by different treatments and which may ultimately define the viability of metastatic clones. Alternatively, these CTCs may represent tumor cells shed from different metastatic sites and therefore reflect tumor heterogeneity. However, despite treatment with more potent androgen signaling inhibitors, *AR* amplification continues to function as a potential resistance mechanism. Accordingly,




Figure 1: CTC capture and validation in LNCAP and mCRPC patients. (A) Flowchart of CTC isolation, detection and molecular analysis workflow. (B) Left panel: LNCAP cells spiked into blood as a model for CTC capture and assay validation; Middle panel: Patient CTC without *AR* amplification; Right panel: Patient CTC with *AR* amplification. Upper panel immunofluorescence: Blue: dapi, Green: CK20, Pink: CD45. Lower panel: *AR* FISH analysis of cell identified in upper panel. Red: *AR* signal, green: *X CEP* control signal.

Table 1: mCRPC patient characteristics and treatment history

Age at bx	
Median (IQR)	70 (57–83)
Gleason score, <i>n</i> (%)	
6	1 (4)
7	7 (28)
8-10	15 (60)
unk	2 (8)
Disease sites, <i>n</i> (%)	
bone	6 (24)
bone + lymph node	9 (36)
Bone + visceral	4 (16)
Bone + lymph node + visceral	1 (4)
Lymph node	4 (16)
Lymph node + visceral	1 (4)
ECOG, <i>n</i> (%)	
0	13 (52)
1	12(48)
Laboratory	
Hemoglobin (media, g/dL; IQR)	12.36 (9.6–14)
Low (< 13.5) <i>n</i> (%)	24 (96)
LDH (median, U/L; IQR)	213 (150–312)
Elevated (> 250), <i>n</i> (%)	4 (16)
Unknown	5 (20)
Albumin (median, g/L;IQR)	3.66 (3.0–4.2)
Low (< 35), <i>n</i> (%)	3 (12)
Normal, (%)	22 (88)
Current treatment, <i>n</i> (%)	
Abiraterone acetate	1 (4)
Enzalutamide	12 (48)
Radium	1 (4)
Docetaxel	
6 (24)	
Lupron	2 (8)
Cab/OGX	1 (4)
None	2 (8)
All treatments received, <i>n</i> (%)	
Abiraterone acetate	9 (36)
Enzalutamide	25 (100)
Docetaxel	1 (4)
Bicalutamide	22 (88)
LBH+Casodex	5 (20)
LHRH Agonist (Lupron, zoladex)	5 (20)
LHRH Antagonist (Degarelix)	25 (100)
Other	10 (40)




Figure 2: AR amplification in matched CTCs and biopsies from mCRPC patients. (A) Representative images of paired CTC and biopsy patient samples without AR gene amplification (left) and paired patient samples expressing AR gene amplification (right). Red: AR signal; Green: Cep X control signal. (B) Results of AR gene expression in CTC samples and paired biopsies of all study subjects.




Figure 3: Heterogeneity of amplification in mCRPC patient CTCs. (A) Bar graph representing the percentage of amplified CTCs (red) and non-amplified CTCs (green) found in mCRPC patients. (B) Intra- and interpatient heterogeneity of AR amplification in CTCs in mCRPC patients is shown graphically. Representative images are depicted of weak (yellow), medium (orange) and strong (purple) AR amplification found in mCRPC patient CTCs. See results for details.

Table 2: AR amplification status in CTCs from mCRPC patients (related to Figure 3)

Study #	Serum PSA at bx	Total # CTCs	# WT CTC	# Amplified CTCs	% of Amplified CTCs
14-114	94.42	19	18	1	5.2
14-11	1.79	12	10	2	16.7
14-74	17.56	27	10	7	25.9
14-99	2137.3	18	13	5	27.8
14.32	1169	13	8	5	38.4
14-104	332.62	57	33	24	42.1
14-87	1859	2	1	1	50
14-77	11.82	48	23	25	52
14-109	425.28	551	22	29	56.9
14-76	4.54	40	11	29	72.5
14-108	10.57	79	21	58	73.4
14-86	120.06	26	6	20	76.9
14-72	37.06	20	20	0	0
14-89	6.18	18	18	0	0
14-88	173.5	6	6	0	0
14-58	48.92	4	4	0	0
14-90	148.39	4	4	0	0
14-106	371.76	1	1	0	0
14-51	109.93	2	0	2	100
14-59	215.9	8	0	8	100
14-4	250	3	0	3	100
14-103	8.33	5	0	5	100
14-116	20.9	40	0	40	100
14-50	41.83	1	0	1	100

the opportunity to perform serial blood draws for CTCs can be used to monitor the emergence of AR amplification.

In summary, our results indicate the potential to expand CTC research through use of a simple, low cost

assay to detect protein and gene expression in CTCs. Our research has shown that AR gene status can be accurately determined in CPRC patients using a non-invasive procedure that utilizes peripheral blood.

PRE-TREATMENT					PROGRESSION			
PATIENT	PSA	BIOPSY SITE	BIOPSY AR	CTC AR	PSA	BIOPSY SITE	BIOPSY AR	CTC AR
50	42	BONE	AMP	AMP	110	LYMPH NODE	AMP	AMP
76	4.5	BONE	AMP	AMP	12	BONE	AMP	AMP
58	49	BONE	NON-AMP	NON-AMP	216	LIVER	AMP	AMP

Figure 4: Documenting AR Amplification status with sequential CTC and biopsies in mCRPC patients. Sequential CTC analysis correlated with baseline and progression biopsies, with two patients having AR amplification at both timepoints, and one patient developing AR amplification at time of progression.

MATERIALS AND METHODS

Patient selection

Patients treated at Oregon Health & Science University with mCRPC were recruited under an institutional review board-approved protocol with informed consent. Specifically, men undergoing pretreatment and disease progression tumor biopsies for mCRPC were recruited under the SU2C/PCF/AACR West Coast Cancer Dream Team biopsy program. This study focuses on the patients recruited between Jan 2014 and June 2015. During that timeframe, 29 men were recruited. Here we report on the results of 25 of those men. Patients were selected based on having a tumor biopsy performed. CTC *AR* amplification results were blindly compared to the current gold standard tumor biopsy result for *AR* gene status. (R1 Q1) Four men were eliminated from the results because a paired tumor biopsy and CTC sample were not attained for various reasons. Two subjects were not tested for *AR* amplification in their tumor biopsy, one sample failed the tumor biopsy *AR* amplification assay and one sample failed the CTC *AR* amplification assay. Fifteen mls of blood for CTC studies were drawn for analysis at time of biopsy. Complete patient demographics are shown in Table 1.

Protocol for isolation of CTCs from patient blood samples

Please see results section for detailed protocol. Blood samples were collected using two EDTA collection tubes. Blood was processed within 24 hours of collection in accordance with the above described protocol. Please see Figure 1A for flowchart.

Immunofluorescent staining of patient samples

Immunofluorescent staining was performed on CTC samples. Slides were removed from -80°C storage and allowed to reach room temperature. Once slides were room temperature they were placed in PBS. Within 20 minutes, permeabilization was performed for 20 minutes using cold methanol stored at -20°C . Slides were rinsed in PBS. Nonspecific binding was blocked using Dako protein block (Dako X090930) for 30 minutes.

Primary antibodies were stained sequentially. First, CK18 1:100 (Santa Cruz Bio # sc-31700) was incubated for 1 hour at room temperature. Slides were rinsed in PBS 2×5 minutes. Secondary antibody Alexa 488 (Life Tech A11034) 1:1000 was diluted in PBS and was incubated at room temperature for 30 minutes. Slides were washed in PBS for 5 minutes. Slides were then incubated for one hour at room temperature with anti-CD45 1:00 (Abcam #ab8216). Slides were rinsed in PBS for 2×5 min. Alexa 647 (Life Tech #A31571) 1:1000 diluted in PBS was

incubated for 30 minutes at room temperature. Slides were rinsed in PBS for 5 minutes. Slides were air dried and immediately coverslipped using mounting media with Dapi (Vector #H-1200). Slides were immediately scanned or stored at 4°C overnight and scanned the next day using Perkin Elmer Midi scanner. Slide image was visually reviewed to determine the number of positive CK18 negative CD45 cells. Following completion of scanning and image review, coverslips were removed from slides by soaking slides in PBS to allow coverslips to float off. Slides were then immediately processed for *AR* FISH probe.

Fluorescent *in situ* hybridization (FISH)

A two color FISH assay was performed using Spectrum Orange *AR* (Xq12) probe (Vysis #30-190040) and Spectrum Green labeled ChrX centromere (Xp11.1-q11.1) *X CEP* (Vysis# 32-112023). Patient slides were permeabilized at 80°C for 5 min in a 2xSCC/formamide solution. Slides were rinsed in PBS and dehydrated through a series of alcohols. Probes were prepared according to manufacturer's instructions and denatured at 72°C for 5 min and hybridized overnight at 32°C using Vysis hybridizer. The next day slides were washed in 2xSCC +0.1% tween solution at 42°C for 2 min then rinsed in room temp PBS, dehydrated and coverslipped using Dako mounting media with Dapi (#H-1200). CTCs were identified by cells that expressed 2 or more copies of *AR* and *X CEP* probe, positive CK18 expression and negative CD45 expression. White blood cells were identified as having 1 copy of *AR* and 1 copy of *X CEP*, negative CK 18 expression and positive CD45 expression.

Automated CTC *AR* FISH quantification

Slides were scanned on a 3D Histech Panoramic scanner. Fluorescent *in situ* hybridization signals were assessed using FishQuant software. *AR* amplification was considered to be present when the *AR* gene to X chromosome ratio was greater than 2. Some leukocytes remained following isolation process and were used as internal controls.

Metastatic CRPC biopsies

Five μm FFPE tissue sections were mounted on positively charged glass slides. One section was stained with H&E and examined by a pathologist, followed by marking of tumor region(s). Slides for FISH were baked in a dry oven at 60°C for 2 hours. They were then cooled briefly and loaded into a Vysis VP2000 slide processor and were then deparaffinized and pretreated. Slides were dried and 5–10 μl of an androgen receptor (*AR*)/ X centromere probe solution were added to each slide. Slides were covered with

glass coverslips, sealed with rubber cement, and placed into a Vysis Thermobrite machine for denaturation/renaturation. Coverslips were soaked off, slides post-washed and air dried before mounting with DAPI I using new glass coverslips. 100 cells were scored for the number of *AR* and centromere signals. Subsequently, fifty interphase cells were scored. A ratio of *AR*:X centromere signals > 2.0 was considered amplified.

Statistical analysis

Positive predictive value, specificity and sensitivity were calculated based on the classification of patients for *AR* status from CTCs and archival tissue. Twenty-nine patients had matched biopsies and CTCs. Of these, 1 biopsy failed *AR* FISH testing, 1 CTC sample failed *AR* FISH testing, and 2 biopsies were inadequate for *AR* FISH. Subsequently, 25 patients were included in the final analysis as they had conclusive FISH results in both CTCs and tumor tissue. Descriptive statistical analyses, including Cohen's kappa testing were performed using GraphPad Prism software.

ACKNOWLEDGMENTS

We thank Mandy Burns and Ashley Sager for administrative support; the Histopathology Shared Resource for pathology support; and the Knight Diagnostic Laboratories for FISH studies on mCRPC biopsies. We would like to express our sincere gratitude to all our participating patients and their families. Dedicated to Wayne and Joan Kingsley for their philanthropic support for prostate cancer.

CONFLICTS OF INTEREST

The authors declare that they have no competing interest

GRANT SUPPORT

This study was supported by NIH grants R01 CA169172, P30 CA069533 and P30 CA069533 13S5 through OHSU-Knight Cancer Institute, the Pacific Northwest Prostate Cancer SPORE/NCI (P50 CA097186); (G.V. T). This research was also supported by a Stand Up to Cancer - Prostate Cancer Foundation - Prostate Dream Team Translational Cancer Research Grant (SU2C-AAACR-DT0409). This research grant is made possible by the generous support of the Movember Foundation. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research (7465sc). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

1. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. *Nat Med.* 2004; 10:33–39.
2. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of *AR* signaling in prostate cancer. *Clin Cancer Res.* 2009; 15:4792–4798.
3. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. *J Clin Oncol.* 2005; 23:8253–8261.
4. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. *Urol Oncol.* 2009; 27:36–41.
5. Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. *Nat Med.* 2016; 22:369–378.
6. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med.* 2004; 351:781–791.
7. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin Cancer Res.* 2008; 14:6302–6309.
8. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. *Eur Urol.* 2016.
9. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med.* 2014; 371:424–433.
10. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, et al. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med.* 2011; 364:1995–2005.
11. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, et al. Characterization of ERG, AR, PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. *Cancer Res.* 2009; 69:2912–2918.

12. Alix-Panabieres C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. *Cancer Discov.* 2016; 6:479–491.
13. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. *Nat Rev Clin Oncol.* 2014; 11:129–144.
14. Attard G, de Bono JS. Utilizing circulating tumor cells: challenges and pitfalls. *Curr Opin Genet Dev.* 2011; 21:50–58.
15. Punnoose EA, Ferraldeschi R, Szafer-Glusman E, Tucker EK, Mohan S, Flohr P, Riisnaes R, Miranda S, Figueiredo I, Rodrigues DN, Omlin A, Pezaro C, Zhu J, et al. PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. *Br J Cancer.* 2015; 113:1225–1233.